Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$56.00
$55.66
$17.15
$56.48
$1.14B2.34301,073 shsN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$19.06
+3.0%
$17.96
$13.30
$25.00
$444.47M1.114,898 shs661 shs
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$6.04
-2.9%
$5.48
$1.97
$22.47
N/A1.39294,189 shs54,968 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00%0.00%0.00%0.00%0.00%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
+3.26%+8.27%+7.76%+12.56%-15.31%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-2.89%-6.21%+6.71%+92.36%-70.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.5135 of 5 stars
3.85.00.00.01.90.00.0
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
1.728 of 5 stars
3.41.00.00.01.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00
N/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00136.15% Upside
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83460.15% Upside

Current Analyst Ratings Breakdown

Latest CIR, SLN, PRTC, and OXB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$786.92M1.45$4.77 per share11.74$7.81 per share7.17
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M94.77$2.46 per share7.76$17.04 per share1.12
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$43.26MN/AN/AN/A$4.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$19.39M$1.3740.8819.51N/A3.40%35.32%5.21%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/21/2025 (Estimated)

Latest CIR, SLN, PRTC, and OXB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.2067N/AN/AN/A$3.38 millionN/A
5/8/2025Q1 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3.34
2.29
1.46
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
8.81
8.81

Institutional Ownership

CompanyInstitutional Ownership
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
96.16%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
1.00%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3,06020.39 million20.19 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.02 million22.75 millionNot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
100N/AN/ANot Optionable

Recent News About These Companies

Silence Therapeutics plc GAAP EPS of -C$0.20
Silence Therapeutics initiated with a Sell at Goldman Sachs
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
(SLN) Investment Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

CIRCOR International stock logo

CIRCOR International NYSE:CIR

CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$19.06 +0.56 (+3.01%)
Closing price 07/18/2025 03:58 PM Eastern
Extended Trading
$19.06 0.00 (-0.01%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$6.04 -0.18 (-2.89%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.05 +0.01 (+0.18%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.